Martin Gutierrez
About
Martin Gutierrez is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Martin Gutierrez has authored 205 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Oncology, 80 papers in Molecular Biology and 51 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Martin Gutierrez's work include Cancer Immunotherapy and Biomarkers (52 papers), Lung Cancer Treatments and Mutations (33 papers) and Lymphoma Diagnosis and Treatment (27 papers). Martin Gutierrez is often cited by papers focused on Cancer Immunotherapy and Biomarkers (52 papers), Lung Cancer Treatments and Mutations (33 papers) and Lymphoma Diagnosis and Treatment (27 papers). Martin Gutierrez collaborates with scholars based in United States, Canada and United Kingdom. Martin Gutierrez's co-authors include Shivaani Kummar, Elaine S. Jaffe, Anthony J. Murgo, James H. Doroshow, Wyndham H. Wilson, Giuseppe Giaccone, Seth M. Steinberg, Richard F. Little, Mark Raffeld and Stefania Pittaluga and has published in prestigious journals such as JAMA, Nucleic Acids Research and Journal of Clinical Oncology.
In The Last Decade
Martin Gutierrez
195 papers receiving 4.4k citations
Peers
Martin Gutierrez
Alejandro D. Ricart United States
Lia Gore United States
Anastasios Stathis Switzerland
Martin Gutierrez United States
John Gutheil United States
Christopher D. Gocke United States
Barrett H. Childs United States
Elizabeth A. Punnoose United States
David Hogg Canada
Núria Viñolas Spain
Citations per year, relative to Martin Gutierrez Martin Gutierrez (= 1×)
peers
Alejandro D. Ricart
Countries citing papers authored by Martin Gutierrez
Since
Specialization
Citations
This map shows the geographic impact of Martin Gutierrez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Gutierrez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Gutierrez more than expected).
Fields of papers citing papers by Martin Gutierrez
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Martin Gutierrez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Gutierrez. The network helps show where Martin Gutierrez may publish in the future.
Co-authorship network of co-authors of Martin Gutierrez
This figure shows the co-authorship network connecting the top 25 collaborators of Martin Gutierrez. A scholar is included among the top collaborators of Martin Gutierrez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Gutierrez. Martin Gutierrez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Davar, Diwakar, Zeynep Eroglu, Mohammed Milhem, et al.. (2025). Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B. Clinical Cancer Research. 31(16). 3443–3451.
2.
Meric‐Bernstam, Funda, Martin Gutierrez, Enrique Sanz‐García, et al.. (2025). Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors. Cancer Research Communications. 5(9). 1664–1673.
3.
Harrington, Kevin J., et al.. (2024). 1007P Systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Initial results from a phase Ia study. Annals of Oncology. 35. S684–S685.
4.
Hamilton, Ashley, Robin Kate Kelley, Daneng Li, et al.. (2024). ATHENA: A phase 1/2 study of AZD5851, a chimeric antigen receptor (CAR) T-cell therapy directed against GPC3 in adult patients with advanced/recurrent hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 42(16_suppl). TPS2675–TPS2675.
5.
Yap, Timothy A., Nehal J. Lakhani, Amita Patnaik, et al.. (2024). First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations.. Journal of Clinical Oncology. 42(16_suppl). 3005–3005.
6.
Noel, Marcus Smith, Bhaskar Srivastava, Scott R. Daigle, et al.. (2024). Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: Clinical update.. Journal of Clinical Oncology. 42(16_suppl). 3083–3083.
7.
Melero, Ignacio, Judy S. Wang, Martin Gutierrez, et al.. (2024). Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study.. Journal of Clinical Oncology. 42(16_suppl). 2588–2588.
8.
Christenson, Eric S., Daruka Mahadevan, Syed Mohammad Ali Kazmi, et al.. (2024). A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.. Journal of Clinical Oncology. 42(16_suppl). 2538–2538.
9.
Albitar, Maher, Andrew Ip, Sally Agersborg, et al.. (2024). Using cell-free RNA in monitoring immune system and the demonstration of significant systemic deficiency in lymphoid and myeloid biomarkers in patients with cancer.. Journal of Clinical Oncology. 42(16_suppl). 3048–3048.
10.
Hong, David S., Michael A. Postow, Bartosz Chmielowski, et al.. (2023). Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clinical Cancer Research. 29(12). 2210–2219.
11.
Pant, Shubham, Dirk Arnold, Josep Tabernero, et al.. (2023). 1621P Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial. Annals of Oncology. 34. S898–S898.
12.
Gutierrez, Martin, Lin Shen, Bo Gao, et al.. (2023). 681P First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors. Annals of Oncology. 34. S476–S477.
13.
Johnson, Melissa L., Mark M. Awad, Martin Gutierrez, et al.. (2023). OA05.05 Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Refractory SCLC: A Subgroup Analysis of a Phase 1/2 Study. Journal of Thoracic Oncology. 18(11). S54–S55.
14.
Pinato, David J., Ruth Plummer, Martin Gutierrez, et al.. (2022). 622 A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099318, in patients with select advanced solid tumors. Regular and Young Investigator Award Abstracts. A654–A654.
15.
Mohrbacher, Ann, Allen S. Yang, Susan Groshen, et al.. (2017). Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial. Clinical Cancer Research. 23(16). 4550–4555.
16.
Kuruvilla, John, Michael R. Savona, Rachid Baz, et al.. (2017). Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 129(24). 3175–3183.
17.
Rajan, Arun, Corey A. Carter, Ronan J. Kelly, et al.. (2012). A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors. Clinical Cancer Research. 18(8). 2344–2351.
18.
Rajan, Arun, Ronan J. Kelly, Jane B. Trepel, et al.. (2011). A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas. Clinical Cancer Research. 17(21). 6831–6839.
19.
Kelly, Ronan J., Arun Rajan, Jeremy Force, et al.. (2011). Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib. Clinical Cancer Research. 17(5). 1190–1199.
20.
Pfister, Thomas D., Ralph E. Parchment, Shivaani Kummar, et al.. (2010). Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells. Clinical Cancer Research. 16(3). 1073–1084.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Alejandro D. Ricart Breakdown of academic impact, for papers by Lia Gore Breakdown of academic impact, for papers by Anastasios Stathis Breakdown of academic impact, for papers by Martin Gutierrez Breakdown of academic impact, for papers by John Gutheil Breakdown of academic impact, for papers by Christopher D. Gocke Breakdown of academic impact, for papers by Barrett H. Childs Breakdown of academic impact, for papers by Elizabeth A. Punnoose Breakdown of academic impact, for papers by David Hogg Breakdown of academic impact, for papers by Núria Viñolas